Peginterferon alfa-2b (Y-shaped pegylation) - Xiamen Amoytop Biotech

Drug Profile

Peginterferon alfa-2b (Y-shaped pegylation) - Xiamen Amoytop Biotech

Alternative Names: Pegberon; Y-shaped pegylated interferon alfa-2b; YPEG-rhIFNα-2b - Xiamen Amoytop Biotech; Ypeginterferon alfa-2b - Xiamen Amoytop Biotech; Ypeginterferon alpha-2b - Xiamen Amoytop Biotech

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C
  • Phase III Hepatitis B

Most Recent Events

  • 10 Apr 2017 Peginterferon alfa-2b is still in phase III trials for Hepatitis B (Combination therapy, Treatment-experienced) in China (SC)
  • 31 Dec 2016 Launched for Hepatitis C (Combination therapy) in China (SC) before December 2016 (Xiamen Amoytop Biotech website, April 2017)
  • 31 Dec 2016 Launched for Hepatitis C (Monotherapy in patients with contraindication to or significant intolerance to ribavirin) in China (SC) before December 2016 (Xiamen Amoytop Biotech website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top